Drug Profile

B -Vaxx

Alternative Names: Anti-HER2 vaccine - Imugene; Anti-HER2-B-cell-peptide-cancer-vaccine; B-Vaxx

Latest Information Update: 26 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ohio State University
Class Cancer vaccines; Peptide vaccines; Peptides
Mechanism of Action ERBB-3 receptor antagonists; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Solid tumours

Most Recent Events

17 Feb 2021 B Vaxx is still in phase II trials for Solid tumours in USA (IM) (Imugene pipeline, February 2021)
27 Mar 2019 Efficacy and adverse events data from a phase I trial in Solid tumours released by Ohio State university
01 Dec 2018 Phase-II clinical trials in Solid tumours in USA (IM), before December 2018 (Imugene pipeline, December 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com